Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Am J Otolaryngol ; 15(5): 358-69, 1994.
Artigo em Inglês | MEDLINE | ID: mdl-7978039

RESUMO

PURPOSE: This study was designed to determine the effects of long-term perioperative pentoxifylline administration on random skin flap survival in an appropriate animal model. A secondary objective was to document bioavailability of pentoxifylline in the animal model by measuring blood levels of parent compound and metabolites at regular intervals and comparing these to levels measured in humans. MATERIALS AND METHODS: A randomized control study of the effects of oral pentoxifylline on the survival of "random" skin flaps was conducted at the animal care facility of an academic tertiary referral center on six randomly selected Yorkshire pigs. Oral pentoxifylline was administered daily to four pigs for 3 months, and two pigs received placebo. Pentoxifylline blood levels for each experimental animal were measured after 4, 8, and 12 weeks of daily dosing. Blood viscosity, fibrinogen, and hematocrit were measured for each of the six animals on day 1, day 30, day 60, and day 91. On day 91, 12 surgical random skin flaps were elevated on each of the six animals and immediately sewn back in the donor bed. Pentoxifylline dosing was continued for 2 weeks, and placebo was continued in control animals. On postoperative day 15, all animals were killed and all flaps were measured individually for area of viability. The outcome measure was the detection of statistically significant increase in survival area in skin flaps of those animals administered perioperative pentoxifylline. RESULTS: No significant augmentation of flap survival was noted in experimental animals when compared with those in the control group; no significant difference was noted between or within groups of experimental animals. Pentoxifylline and metabolite blood levels in all experimental animals at every interval were noted to be comparable to those documented in human studies; metabolite concentrations conformed to expected patterns as observed in humans. No significant alterations of blood viscosity, fibrinogen, or hematocrit were measured in the experimental animals when compared with those in the control group. The only animal showing mean flap survival outside the 95% confidence interval was one in the control group. CONCLUSION: No augmentation of random skin flap survival could be shown in the pig model after a 3 month regimen of daily oral pentoxifylline. Blood levels of pentoxifylline in experimental animals were compared with those documented in humans. No alteration of blood viscosity, fibrinogen, or hematocrit was noted in any of the experimental animals when compared with each other or with those in the control group.


Assuntos
Pentoxifilina/uso terapêutico , Transplante de Pele/fisiologia , Administração Oral , Animais , Disponibilidade Biológica , Viscosidade Sanguínea/efeitos dos fármacos , Modelos Animais de Doenças , Feminino , Fibrinogênio/análise , Sobrevivência de Enxerto/efeitos dos fármacos , Hematócrito , Humanos , Pentoxifilina/administração & dosagem , Pentoxifilina/sangue , Pentoxifilina/farmacocinética , Placebos , Pré-Medicação , Fluxo Sanguíneo Regional/efeitos dos fármacos , Transplante de Pele/métodos , Transplante de Pele/patologia , Suínos
2.
Otolaryngol Head Neck Surg ; 100(6): 623-30, 1989 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-2501742

RESUMO

"Lethal midline granuloma" is an unusual but devastating spectrum of lymphoproliferative disorders that is now thought to include four entities: idiopathic midline destructive disease, Wegener's granulomatosis, polymorphic reticulosis, and nasal lymphoma. These disorders must be considered in the differential diagnosis of any patient with chronic, nonspecific complaints localized to the upper airway. An aggressive diagnostic and therapeutic approach may significantly decrease morbidity and death resulting from these lesions.


Assuntos
Granuloma Letal da Linha Média/diagnóstico , Idoso , Idoso de 80 Anos ou mais , Alquilantes/uso terapêutico , Diagnóstico Diferencial , Granuloma Letal da Linha Média/tratamento farmacológico , Granulomatose com Poliangiite/diagnóstico , Granulomatose com Poliangiite/tratamento farmacológico , Humanos , Linfoma/classificação , Linfoma/diagnóstico , Linfoma/tratamento farmacológico , Masculino , Síndrome
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...